Li Wen,Luo Tongyong,Wang Fei,et al.Clinical efficacy of azithromycin for treatment of Mycoplasma pneumoniae pneumonia with gene mutations at site A2063G of 23S rRNA in children[J].Journal of Chongqing Medical University,2025,50(11):1569-1572.
Li Wen,Luo Tongyong,Wang Fei,et al.Clinical efficacy of azithromycin for treatment of Mycoplasma pneumoniae pneumonia with gene mutations at site A2063G of 23S rRNA in children[J].Journal of Chongqing Medical University,2025,50(11):1569-1572. DOI: 10.13406/j.cnki.cyxb.003783.
Clinical efficacy of azithromycin for treatment of Mycoplasma pneumoniae pneumonia with gene mutations at site A2063G of 23S rRNA in children
0.05)。但呼吸道症状突变组比非突变组持续时间更长[(11.51±3.31) d vs. (10.06±3.63) d],差异有统计学意义(
P
<
0.05)。
结论
2
阿奇霉素对23S rRNA的A2063G基因位点突变肺炎支原体仍具有治疗作用。
Abstract
Objective
2
To observe the clinical efficacy of azithromycin for the treatment of
Mycoplasma pneumoniae
pneumonia(MPP) with gene mutations at site A2063G of 23S rRNA in children.
Methods
2
Data were retrospectively collected for 242 children diagnosed with MPP at Sichuan Provincial Maternity and Child Health Care Hospital from January to December 2023,in whom MPP was detected using targeted next-generation sequencing(tNGS). According to the presence or absence of mutations,the children were classified into mutation group(88 cases) and non-mutation group(154 cases).
Results
2
Gene mutations at site A2063G of 23S rRNA were detected in 88 patients. The chest X-rays of both groups showed more lesions in the right lung than in the left lung. Both groups were treated with azithromycin and compared for differences in age,sex,duration of fever,C-reactive protein level,time to improvement of chest X-rays,days of medication,and response rate,with no significant differences found in the above indicators(
P
>
0.05). However,the duration of respiratory symptoms was significantly longer in the mutation group than in the non-mutation group [(11.51±3.31) d vs. (10.06±3.63) d,
P
<
0.05
]
.
Conclusion
2
Azithromycin is effective in treating MPP with gene mutations at site A2063G of 23S rRNA.
关键词
Keywords
references
Diaz MH , Benitez AJ , Winchell JM . Investigations of Mycoplasma pneumoniae infections in the United States:trends in molecular typing and macrolide resistance from 2006 to 2013 [J ] . J Clin Microbiol , 2015 , 53 ( 1 ): 124 - 130 .
Cheng Y , Cheng YJ , Dai SZ , et al . The prevalence of Mycoplasma pneumoniae among children in Beijing before and during the COVID-19 pandemic [J ] . Front Cell Infect Microbiol , 2022 , 12 : 854505 .
Gao LW , Yin J , Hu YH , et al . The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China:2006 to 2016 [J ] . Epidemiol Infect , 2019 , 147 : e192 .
Li SS , Zhang YP , Liu XX . Efficacy of Modified Maxing Shigan Decoction combined with azithromycin sequential therapy in the treatment of children with myco-plasma pneumonia and its influence on children’s serum inflammatory factors and oxidative stress response [J ] . J Clin Exp Med , 2023 , 22 ( 8 ): 870 - 875 .
Zhang L , Yin L , Shang SQ . Effect of budesonide combined with azithromycin on refractory mycoplas-ma pneumonia in children and its influence on immune function [J ] . J N Sichuan Med Coll , 2023 , 38 ( 4 ): 496 - 499,504 .
National Health Commission . Guidelines for Diagnosis and Treatment of Mycoplasma Pneumonia in Children(2023) [J ] . Clinical Education of General Practice , 2023 , 21 ( 3 ): 196 - 202 .
Chen Y . Effect of doxycycline in the treatment of macrolide resistant Mycoplasma pneumoniae pneumonia in children [J ] . Syst Med , 2024 , 9 ( 9 ): 157 - 160 .
Yang HJ . Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children [J ] . Korean J Pediatr , 2019 , 62 ( 6 ): 199 - 205 .
Cardinale F , Chironna M , Dumke R , et al . Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia [J ] . Eur Respir J , 2011 , 37 ( 6 ): 1522 - 1524 .
Expert Committee on Rational Use of Medicines for Children Pharmaceutical Group,National Health and Family Planning Commission . Expert consensus on laboratory diagnostics and clinical practice of Mycoplasma pneumoniae infection in children in China(2019) [J ] . Chin J Pediatr , 2020 , 58 ( 5 ): 366 - 373 .
Pereyre S , Guyot C , Renaudin H , et al . In vitro s election and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae [J ] . Antimicrob Agents Chemother , 2004 , 48 ( 2 ): 460 - 465 .
Pan MA , Zhang TT , Zhu JX , et al . The study of drug resistance and mechanism of azithromycin for Mycoplasma pneumoniae [J ] . Chin J Antibiot , 2010 , 35 ( 9 ): 721 - 725 .
Zhang T . Study on the correlation between drug resistance of Mycoplasma pneumoniae in children and clinical medication [D ] . Guangzhou : Guangzhou Medical University , 2014 .
Yamazaki T , Kenri T . Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae [J ] . Front Microbiol , 2016 , 7 : 693 .
Chou CC , Shen CF , Chen SJ , et al . Recommendations and guidelines for the treatment of pneumonia in in Taiwan Province of China [J ] . J Microbiol Immunol Infect , 2019 , 52 ( 1 ): 172 - 199 .
Huang X , Li D , Liu F , et al . Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia [J ] . BMC Infect Dis , 2021 , 21 ( 1 ): 14 .
A multi-center randomized contorlled clinical trial of doxycycline versus azithromycin injection in treatment of urinary tract infections.
Effect of azithromycin on intragastric pressure and gastric electrical activity
Related Author
YUAN Zhe
et al
钟良宝
刘振湘
陈文
et al
陆杰
LI Jing
Related Institution
Department of Infectious Diseases,the First Affiliated Hospital,Chongqing Medical University, Key Laboratory of Chongqing Infectious and Parasitic Diseases